Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Non-Current Liabilities (2017 - 2025)

Aclaris Therapeutics has reported Total Non-Current Liabilities over the past 9 years, most recently at $46.4 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $46.4 million for Q4 2025, down 17.29% from a year ago — trailing twelve months through Dec 2025 was $46.4 million (down 17.29% YoY), and the annual figure for FY2025 was $46.4 million, down 17.29%.
  • Total Non-Current Liabilities for Q4 2025 was $46.4 million at Aclaris Therapeutics, up from $44.8 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for ACRS hit a ceiling of $56.1 million in Q4 2024 and a floor of $18.0 million in Q2 2024.
  • Median Total Non-Current Liabilities over the past 5 years was $44.6 million (2021), compared with a mean of $39.4 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 193.07% in 2023 and later tumbled 66.57% in 2024.
  • Aclaris Therapeutics' Total Non-Current Liabilities stood at $51.7 million in 2021, then plummeted by 53.82% to $23.9 million in 2022, then soared by 42.52% to $34.0 million in 2023, then soared by 64.79% to $56.1 million in 2024, then decreased by 17.29% to $46.4 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $46.4 million (Q4 2025), $44.8 million (Q3 2025), and $46.9 million (Q2 2025) per Business Quant data.